Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials.

IF 4.3 2区 医学 Q2 ONCOLOGY Therapeutic Advances in Medical Oncology Pub Date : 2025-01-10 eCollection Date: 2025-01-01 DOI:10.1177/17588359241288251
Cristina Gurizzan, Michela Cinquini, Lorenzo Legramandi, Carlo Resteghini, Marco Siano, Cristiana Bergamini, Luigi Lorini, Davide Smussi, Alberto Paderno, Lisa Licitra, Paolo Bossi
{"title":"Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials.","authors":"Cristina Gurizzan, Michela Cinquini, Lorenzo Legramandi, Carlo Resteghini, Marco Siano, Cristiana Bergamini, Luigi Lorini, Davide Smussi, Alberto Paderno, Lisa Licitra, Paolo Bossi","doi":"10.1177/17588359241288251","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a non-negligible rate of severe toxic effects. Treatment-related death (TRD) is a crucial topic for physicians involved in the curative treatment of HNC. This meta-analysis aimed to better address TRD in locally advanced HNC patients treated with CRT through available and relevant literature.</p><p><strong>Methods: </strong>We performed a systematic review of the literature according to the PRISMA statement. The studies fulfilling these criteria included the following: concurrent or alternating CRT; both radical and postoperative settings; published from 2000 to 2020; involving 100+ patients; and available toxicity data. TRD was defined as death occurring from CRT start until a month from the end of CRT. Potential TRD predictors were evaluated.</p><p><strong>Results: </strong>In all, 65 studies were retrieved, with a total of 235 TRDs reported accounting for an overall risk rate of 1.4%. At meta-regression analysis, T stage and neutropenia grade >3 were potential predictors of higher TRD risk, both in univariate and multivariate analyses. Considering only the studies reporting at least one event, laryngeal/hypopharyngeal, oral cavity subsites and renal failure were significant predictors for TRD. The oropharyngeal subsite was protective in both analyses. None of the predictors proved to be independently correlated with TRD at multivariable analysis.</p><p><strong>Conclusion: </strong>CRT in HNC resulted in 1.4% of TRDs. TRD rate reduction may imply better patient selection and more intensive supportive care programs.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241288251"},"PeriodicalIF":4.3000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724409/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241288251","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a non-negligible rate of severe toxic effects. Treatment-related death (TRD) is a crucial topic for physicians involved in the curative treatment of HNC. This meta-analysis aimed to better address TRD in locally advanced HNC patients treated with CRT through available and relevant literature.

Methods: We performed a systematic review of the literature according to the PRISMA statement. The studies fulfilling these criteria included the following: concurrent or alternating CRT; both radical and postoperative settings; published from 2000 to 2020; involving 100+ patients; and available toxicity data. TRD was defined as death occurring from CRT start until a month from the end of CRT. Potential TRD predictors were evaluated.

Results: In all, 65 studies were retrieved, with a total of 235 TRDs reported accounting for an overall risk rate of 1.4%. At meta-regression analysis, T stage and neutropenia grade >3 were potential predictors of higher TRD risk, both in univariate and multivariate analyses. Considering only the studies reporting at least one event, laryngeal/hypopharyngeal, oral cavity subsites and renal failure were significant predictors for TRD. The oropharyngeal subsite was protective in both analyses. None of the predictors proved to be independently correlated with TRD at multivariable analysis.

Conclusion: CRT in HNC resulted in 1.4% of TRDs. TRD rate reduction may imply better patient selection and more intensive supportive care programs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受化疗和放疗的头颈癌患者的治疗相关死亡率:已发表试验的荟萃分析结果
目的:探讨局部晚期头颈癌(HNC)的化疗与放疗联合治疗方法。综合放化疗(CRT)治疗导致不可忽视的严重毒性效应。治疗相关性死亡(TRD)是参与HNC根治性治疗的医生的一个重要课题。本荟萃分析旨在通过现有的相关文献更好地解决接受CRT治疗的局部晚期HNC患者的TRD问题。方法:我们根据PRISMA声明进行了系统的文献综述。符合这些标准的研究包括:同步或交替CRT;根治和术后情况;2000年至2020年出版;100+例;以及可用的毒性数据。TRD定义为从CRT开始到CRT结束后一个月内发生的死亡。评估潜在的TRD预测因子。结果:共检索到65项研究,报告了235例trd,总风险率为1.4%。在荟萃回归分析中,无论是单因素分析还是多因素分析,T期和中性粒细胞减少等级>.3都是TRD风险较高的潜在预测因素。仅考虑报告至少一个事件的研究,喉/下咽、口腔亚位和肾功能衰竭是TRD的重要预测因素。口咽亚位在两种分析中都具有保护作用。在多变量分析中,没有一个预测因子被证明与TRD独立相关。结论:CRT在HNC中的TRDs发生率为1.4%。TRD率的降低可能意味着更好的患者选择和更强化的支持性护理方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.20
自引率
2.00%
发文量
160
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).
期刊最新文献
Extracellular vesicles-a new player in the development of urinary bladder cancer. Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC. Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials. Enhancing rare cancer care in developing countries through patient advocacy: insights from the Desmoid Tumor Brazilian Association. Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1